Annual Report of the Company for Financial Year 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Biotech has sent out the notice for its 33rd Annual General Meeting scheduled for Friday, 26th September 2025 at 3:00 PM via video conferencing, along with the Annual Report for FY 2024-25. Shareholders will consider adopting the audited standalone and consolidated financial statements, declare a final dividend of Rs. 2 per equity share (aggregating Rs. 165.27 lakh on 82,63,700 shares), and approve the re-appointment of three directors (Mrs. Manju Singla, Mr. Raja Singla, Mr. Udit Singla) who retire by rotation. The AGM also seeks approval to re-appoint both Managing Directors — Mr. Naresh Kumar Singla and Mr. Suresh Chand Singla — for a fresh five-year term from April 2026 to March 2031, with monthly salary starting at Rs. 8,00,000 from October 2025 (capped at Rs. 20,00,000). Additional resolutions include raising remuneration of two Whole-Time Directors to Rs. 13,50,000/month, regularising the appointment of a new Independent Director, authorising loans up to Rs. 12 crore, enabling mortgage of assets for borrowings up to Rs. 25 crore, appointing a new Secretarial Auditor for five years, ratifying Cost Auditor fees of Rs. 60,000, and approving material related party transactions with Phoenix Bio Sciences, Peptech Biosciences, and Stalwart Nutritions.
Routine AGM-related filing — the Rs. 2 per share dividend is a modest payout for shareholders. The significant boost in promoter-director remuneration and re-appointments of promoter MDs for another five-year term reinforces continued family control, while the proposed loans and borrowings up to Rs. 25 crore signal potential capacity expansion or working capital needs.